OFS
AIMT

OneAscent Financial Services’s Aimmune Therapeutics AIMT Stock Holding History

OneAscent Financial Services’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-13,452
Closed -$225K – 206
2020
Q2 		$225K Buy
13,452
+1,153
+9% +$19.6K 0.15% 149
2020
Q1 		$177K Buy
12,299
+1,488
+14% +$38K 0.13% 136
2019
Q4 		$362K Buy
+10,811
New +$302K 0.2% 90
2019
Q3 		– Sell
-13,107
Closed -$273K – 221
2019
Q2 		$273K Buy
+13,107
New +$270K 0.19% 130

Other funds holding AIMT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

OneAscent Financial Services's AIMT Position: Q3 2020 in Review

OneAscent Financial Services sold out of Aimmune Therapeutics (AIMT) in Q3 2020, closing a stake of 13,452 shares — an estimated $225K sold.

OneAscent Financial Services first reported a position in AIMT in Q2 2019 and held it in 4 quarters. The position peaked at $362K in Q4 2019. 188 funds tracked by Wall St. Rank hold AIMT as of Q3 2020.

  • OneAscent Financial Services reported no remaining Aimmune Therapeutics position as of Q3 2020 after selling out during the quarter.
  • OneAscent Financial Services sold 13,452 Aimmune Therapeutics shares in Q3 2020, an estimated $225K.
  • OneAscent Financial Services first reported a position in Aimmune Therapeutics in Q2 2019 and held it in 4 quarters.
  • OneAscent Financial Services's Aimmune Therapeutics position peaked at $362K in Q4 2019.
  • 188 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2020.

Based on OneAscent Financial Services's 13F filing for Q3 2020, filed 2 Nov 2020.